The Korea Drug Development Fund (KDDF) has selected 10 outstanding examples of new drug development over the past three years, including those carried out by Daewoong Pharmaceutical and CellBion.On Tuesday, the KDDF held the “Presentation of Outstanding National New Drug Development Projects for 202
Celltrion Healthcare said on Tuesday that Vegzelma (bevacizumab), a biosimilar to Genentech’s Avastin for treating metastatic colorectal and breast cancer, is now a preferred drug on Ventegra's U.S. formulary.Ventegra, a leading Pharmacy Benefit Manager (PBM) in the U.S., oversees reimbursement for
SAN DIEGO, Calif. – By Lee Han-soo/Korea Biomedical Review correspondent -- A new study on the treatment of Extranodal NK/T-cell lymphoma (ENKTL) using a combination of isatuximab and cemiplimab has shown promising results, as reported by Professor Kim Seok-jin at Samsung Medical Center during the A
SAN DIEGO, Calif. – By Lee Han-soo/Korea Biomedical Review correspondent -- A recent study presented at the American Society of Hematology (ASH) 2023 conference in San Diego has highlighted the potential benefits of combining AbbVie's epcoritamab and lenalidomide for patients with relapsed/refractor
Daewoong Pharmaceutical said Monday that it has signed an exclusive license agreement with UAE-based Zydus Worldwide DMCC, a wholly owned subsidiary of Zydus Lifesciences headquartered in India, to co-develop and commercialize leuprolide acetate for depot suspension, DWJ108U, in the U.S.The contract
Yuhan Corp.’s epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) treatment Leclaza (lazertinib mesylate monohydrate) has won full approval in Korea.Yuhan said Monday that the company has won approval from the Ministry of Food and Drug Safety (MFDS) for chang
Clinical data of tuspetinib, a new drug for acute myeloid leukemia (AML) developed by Hanmi Pharm, has been released at the annual meeting of the American Society of Hematology (ASH 2023), drawing keen attention.Hanmi Pharm said its partner company Aptose Biosciences presented oral clinical data on
Jeil Pharmaceutical said Monday it has signed an exclusive distribution agreement with Novartis Korea for the sale and supply of Novartis' nine drugs (eye drops) for glaucoma and conjunctivitis.This marks Jeil's inaugural venture into the ophthalmic field. Beginning January 2024, the company aims to
Bigsome Bio, a subsidiary of Lotte Chilsung Beverage, which specializes in customized health functional food, has declined to comment on the possibility of business collaboration with Lotte Healthcare within the same conglomerate.As the healthcare industry emerges as the future growth engine for the
SAN DIEGO, Calif. – By Lee Han-soo/Korea Biomedical Review correspondent -- Korean researchers have presented evidence that brings people a step closer to achieving the goal of treatment-free remission (TFR) in the treatment of chronic myeloid leukemia (CML). Capturing significant attention, the res
SAN DIEGO, Calif. – By Lee Han-soo/Korea Biomedical Review correspondent -- The 65th American Society of Hematology (ASH) opened the world's largest hematology conference in San Diego, Calif, the U.S., on Saturday.According to the organizers, the exhibition will be participated by 275 exhibitors and
Roche's drug Columvi (glofitamab), designed to treat diffuse large B cell lymphoma (DLBCL), has received approval in Korea.The Ministry of Food and Drug Safety (MFDS) said Thursday that it gave the go-ahead to the Swiss-based pharma’s orphan drug.Columvi is a CD20/CD3 bispecific antibody that binds
BMS Korea’s plaque psoriasis drug Sotyktu (deucravacitinib) has failed to cross the Pharmaceutical Benefits Evaluation Committee threshold, carrying the tag “conditional approval.”The drug won the Ministry of Food and Drug Safety (MFDS)’s approval in August and quickly applied for reimbursement but
GSK's immunotherapy Jemperli (dostarlimab) is set to play a key role in the second-line treatment of patients with recurrent or advanced endometrial cancer who have run out of treatment options, a local expert said."Until now, it has been difficult to find an alternative to chemotherapy for the trea
On Thursday, SK bioscience announced the reshuffling of its departments and the appointment of Kim Joon-mo, a former Pfizer executive, to vice president.Starting from Dec.13, the company will operate six departments, namely Business Development (BD), Bio Research, Development, L HOUSE Factory, Quali
Korea Drug Development Fund (KDDF) has selected four companies -- Medytox, TiumBio, AbClon, and MedPacto as part of its “2023 third National New Drug Development Project”.The project is an inter-ministerial research and development (R&D) project that supports the entire cycle of new drug development
Sanofi Korea said its high-dose influenza vaccine Efluelda, designed for seniors, received marketing authorization from the Ministry of Food and Drug Safety on Nov. 29.Efluelda is the first high-dose influenza vaccine approved in Korea for the elderly, preventing influenza caused by type A and B vir
Celltrion said it has signed a joint research agreement with Cyron Therapeutics, a Korean company specializing in antibody discovery and development, for the development of cancer drugs based on multi-antibodies.Under the accord, Celltrion will provide target antibody clones to Cyron, and Cyron will
The Korean securities industry is revising upward the stock price targets for traditional pharmaceutical companies, pointing to licensing deals and export growth.As per the investment banking (IB) sector, domestic securities firms are upwardly adjusting target prices for major traditional pharmaceut
Kwangdong Pharmaceutical said it had signed a memorandum of understanding regarding the transfer of shares of BL Healthcare from BL Pharmtech, the largest shareholder.Under the accord, Kwangdong has agreed to acquire 58.74 percent of BL Healthcare from BL Pharmtech.The key provisions of the MOU incl